New research identifies two drug classes that could be re-purposed for type 1 diabetes treatment

Credit: CC0 Public Domain

Researchers from the Indiana Biosciences Research Institute (IBRI), a leading independent, industry-inspired applied research institute, and Université Libre de Bruxelles (ULB) Center for Diabetes Research, identified two classes of compounds that prevent most of the effects of interferon-α (IFNα) on human beta cells, paving the way for potential future clinical trials of treatments for type 1 diabetes…

Read Entire Article Here…

Leave a Reply

Your email address will not be published. Required fields are marked *